Indication
Urologic Cancer
7 clinical trials
6 products
Clinical trial
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)Status: Recruiting, Estimated PCD: 2028-01-01
Product
NiraparibClinical trial
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 MutationsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
NanoDoceClinical trial
Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial CarcinomaStatus: Completed, Estimated PCD: 2021-11-02
Clinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved TherapiesStatus: Completed, Estimated PCD: 2022-01-12
Product
A166Clinical trial
An Expanded Access Program of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)Status:
Clinical trial
Prevention of Thromboembolism With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy: A Randomized Placebo-Controlled, Double-Blind Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Product
RivaroxabanClinical trial
Radiotherapy in Combination With Pembrolizumab in Patients With PSA Persistence or Biochemical Recurrence After Radical Prostatectomy Due to Prostate CancerStatus: Recruiting, Estimated PCD: 2025-07-01
Product
Pembrolizumab